

**Confirmed Minutes of the
WHSSC Joint Committee Meeting held **In Public** on
Tuesday 19 September 2023
In Person and via MS Teams**

Members:

Kate Eden	(KE)	Chair, WHSSC
Sian Lewis	(SL)	Managing Director, WHSSC
Carole Bell	(CB)	Director of Nursing Quality
Carolyn Donoghue	(CD)	Independent Member, WHSSC
Iolo Doull	(ID)	Medical Director, WHSSC
Richard Evans	(RE)	Executive Medical Director, Swansea Bay UHB
James Leaves	(JL)	Interim Director of Finance and Information, WHSSC
Steve Moore	(SM)	Chief Executive Officer, Hywel Dda UHB (via Teams)
Chantal Patel	(ChP)	Independent Member, WHSSC
Nicola Prygodzicz	(NP)	Chief Executive Officer, Aneurin Bevan UHB
Suzanne Rankin	(SR)	Chief Executive Officer, Cardiff and Vale UHB
Carol Shillabeer	(CS)	Interim Chief Executive Officer, Betsi Cadwaladr UHB (via Teams)
Steve Spill	(SS)	Independent Member, WHSSC
Hayley Thomas	(HTh)	Interim Chief Executive Officer, Powys teaching HB (via Teams)

Deputies:

Linda Prosser	(LP)	Executive Director of Transformation and Strategy, CTMUHB
---------------	------	--

In Attendance:

Stuart Davies	(SD)	Programme Manager, WHSSC
Claire Harding	(CH)	Assistant Director of Planning, WHSSC
Stephen Harray	(SH)	Board Director / Chief Ambulance Service Commissioner, Corporate Development, NCCU & EASC (via Teams for item 3.4 only)
Nicola Johnson	(NJ)	Director of Planning, WHSSC
Jacqui Maunder- Evans	(JME)	Committee Secretary & Associate Director of Corporate Services, WHSSC
Sian Morgan	(SMg)	Consultant Clinical Scientist, AWMGS Laboratory Director (via Teams for item 2.1 only)
Karen Preece	(KP)	Programme Director, Welsh Kidney Network
Ian Phillips	(IP)	Independent Chair, Welsh Kidney Network (via Teams)
David Roberts	(DR)	Director for Mental Health & Vulnerable Groups, WHSSC
Helen Tyler	(HT)	Head of Corporate Governance, WHSSC

Joanna Williams (JW) Programme Director Welsh Sexual Health Assault Services (SARC) (via Teams for item 3.4 only)

Nick Wood (NW) Deputy Chief Executive NHS Wales, Health and Social Services Group, Welsh Government (via Teams)

Observing:

Kerryn Lutchman-Sing (KLS) Assistant Medical Director, WHSSC

Stacey Taylor (ST) Deputy Director of Finance, NHS Wales Delivery Unit

Apologies:

Paul Mears (PM) Chief Executive Officer, Cwm Taf Morgannwg UHB

Minutes:

Gemma Trigg (GT) Corporate Governance Officer, WHSSC

Min Ref	Agenda Item
JC23/113	<p>1.1 Welcome and Introductions</p> <p>The Chair welcomed Members in Welsh and English and thanked members for coming to the Welsh Health Specialised Services (WHSSC) offices to hold the meeting in person and welcomed those who joined the meeting virtually. The Chair stated that future meetings would continue to be held virtually via MS Teams until the next scheduled in person meeting in March 2024. The Chair reminded Members of the purpose of the Joint Committee and the WHSSC values of respect, partnership, improvement and innovation.</p> <p>Introductions were made and members noted that Kerryn Lutchman-Sing, Assistant Medical Director for WHSSC and Stacey Taylor, NHS Wales Delivery Unit, attended as observers.</p> <p>There were no objections to the meeting being recorded for administrative purposes. It was noted that a quorum had been achieved.</p>
JC23/114	<p>1.2 Apologies for Absence</p> <p>Apologies for absence were noted and listed as above.</p>
JC23/115	<p>1.3 Declarations of Interest</p> <p>The Joint Committee (JC) noted the standing declarations. Chantal Patel (ChP) raised one Declaration under the Chair's Report relating to the appointment of the Vice Chair. It was agreed that ChP would leave the meeting for Item 3.1.</p>

Min Ref	Agenda Item
	<p>There were no additional declarations of interest made relating to the items for discussion on the agenda.</p>
JC23/116	<p>1.4 Minutes of the meetings held on 18 July 2023 and 1 August 2023 and Matters Arising</p> <p>The minutes of the JC meeting held on 18 July 2023 and the Extraordinary JC meeting held on 1 August 2023, were received and approved as a true and accurate record of discussions.</p> <p>There were no matters arising.</p>
JC23/117	<p>1.5 Action Log</p> <p>The action log was received, and members noted the progress on the actions outlined on the action log and approved actions that had been closed.</p>
JC23/118	<p>2.1 Genomics Update</p> <p>The presentation outlining how the All Wales Medical Genomics Service (AWMGS) was leading the way in the Rare Disease, Cancer, Pharmacogenomics and Mental Health areas of Genomics was received. The presentation covered the work being taken forward in prevention, diagnosis and targeted treatments being used where there is a clinical need.</p> <p>Sian Morgan (SMg) presented the key updates and members noted the Genomics Delivery Plan for Wales 2022-2025 and the way that the field of Genomics had, and continued to, transform cancer diagnostics and treatment. Members noted that the aim of the AWMGS was to deliver equitable genomic testing for improved outcomes in cancer and rare disease enabling precision medicine prescribing and reducing adverse reactions. The service, however, was at risk of inequity due to the restructuring of the Genomics within NHS England (NHSE).</p> <p>Members noted the patient story of Craig Maxwell a 41-year-old dad of two who had been diagnosed with stage 4-lung cancer, had been raising the profile for the QuicDNA testing, and had raised over £350k towards improving cancer diagnosis in Wales.</p> <p>Suzanne Rankin (SR) highlighted that currently only those therapies that had been approved by the National Institute for Health and Care Excellence (NICE) were funded and emphasised the challenges Health Boards (HBs) had financially, as well as regarding capacity to be able to service the pathway. SR suggested that more strategic thought needed to be given as to how these opportunities were being commissioned in Wales so the requirements were captured</p>

Min Ref	Agenda Item
	<p>across the whole pathway and not just for therapies to reduce inequitable access.</p> <p>Nick Wood (NW) agreed that there was a very compelling case to expand in this area and that there was a need to look at the way testing was conducted, reporting mechanisms on Genomics services in Wales and a need to review the wider diagnostics agenda. NW highlighted the importance of bringing this to the top of everyone's agenda to enable changes in treatment and diagnosis as a priority.</p> <p>ChP thanked SMg for the informative presentation and queried whether there were any ethical issues that would need to be managed as a result of any incidental findings for example General Data Protection Regulation GDPR (GDPR) issues, and what measures would be taken to mitigate those issues. SMg gave an assurance that impact assessments were undertaken to consider any broader compliance factors.</p> <p>Steve Moore (SM) praised the work being done by the service and how it was creating curative possibilities in an area where there were none previously. SM queried what the future investment profile of precision medicine would be, what advanced therapeutics may look like, what costs would be involved when looking at the whole pathway, including all local diagnostic services, and how the inequity issues were going to be addressed to increase awareness of the services provided and how to access them.</p> <p>Nicola Prygodzicz (NP) supported the plan to raise the profile with all HBs and Welsh Government (WG) being involved and the need to create a clear pathology strategy and address workforce issues to ensure changes could be implemented.</p> <p>Linda Prosser (LP) queried what the impact would be on traditional services and what the future model would mean in terms of savings and whether those savings could be incorporated into the financial planning.</p> <p>SR informed members that an integrated national pathology service would have to consider how to best use existing resources and digital cellular pathology service would need to be in place in order to embed any pathology service. SR explained the difficulty in terms of existing levels of demand and future savings as these new novel therapies would move patients from short-term cancer patients to long-term condition patients who may need lifelong support and therefore convert existing levels of demand into a different type of demand.</p>

Min Ref	Agenda Item
	<p>Stuart Davies (SD) emphasised that there would be some cost saving opportunities in pharmacogenomics with the implementation of DPYD testing resulting in a potential saving of £5m and agreed that there was a need to identify the long term consequences of improved outcomes for patients.</p> <p>SMg noted that the All Wales Clinical Oncology Group (AWCOG), whose remit was to ensure there was an all Wales equitable pathway around recommendations of testing as well as education, met on a regular basis including Cell Pathologist Lead representation from West, North and East Wales. Members noted that lung cancer outcomes in Wales were one of the poorest across Europe and the urgent need to improve outcomes for patients.</p> <p>The Chair thanked SMg for sharing some of the success stories and the progress that had been made by the service.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the presentation.
JC23/119	<p>3.1 Chair's Report</p> <p>The Chair's report was received and members noted:</p> <ul style="list-style-type: none"> • the Appointment of a Vice Chair – Due to ChPs Declaration of Interest ChP was asked to leave the room for this item. The Chair proposed that, in order to ensure effective business continuity for WHSSC and the Joint Committee, it was proposed that Chantal Patel, Independent Member (IM), WHSSC be appointed to the unremunerated role of Vice Chair for the Joint Committee, in accordance with the WHSSC Standing Orders (SOs), • Chair of the Individual Patient Funding Request (IPFR) Panel - Further to the Extraordinary Joint Committee meeting held on 1 August 2023, which supported the request to take forward the urgent recruitment of the WHSSC Individual Patient Funding Request (IPFR) panel Chair and which approved the proposed remuneration package, the post had now been advertised following earlier delays. The aim was to appoint a substantive IPFR Chair by the end of October 2023. Interim arrangements had been put in place to cover meetings during October 2023; • Chair of the Quality Patient Safety Committee – Carolyn Donoghue (CD), Independent Member, WHSSC had taken on the Chairs role for the WHSSC Quality & Patient Safety Committee (QPSC) and will attend her first meeting as Chair in October 2023; and • Key meetings attended.

Min Ref	Agenda Item
	<p>The Chair also provided an update on the Establishment of a WHSSC/Emergency Ambulance Services Committee (EASC) Vacancy Control Panel following both WHSSC and EASC receiving a letter sent on behalf of the CEOs imposing an immediate recruitment freeze. Members noted that although this request did not align with the governance arrangements for the Joint Committee, it was agreed that WHSSC and EASC would establish a joint Vacancy Control Panel, aligned with that of CTMUHB but that was also responsive to the needs of both functions.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the report, • Note the update on the recruitment of the Chair of the Independent Patient Funding Request (IPFR) Panel, • Approve the appointment of Chantal Patel as Vice Chair of the WHSSC Joint Committee; and • Note the establishment of the WHSSC/EASC Vacancy Control Panel.
JC23/120	<p>3.2 Managing Director's Report</p> <p>The Managing Director's Report was received and members noted the following updates:</p> <ul style="list-style-type: none"> • Progress on South Wales Neonatal ODN - Funding for the South Wales Neonatal Transport Operational Delivery Network (ODN) was agreed at the 14 March 2023 Joint Committee meeting and funding had been released. However, the recruitment process had not yet taken place in line with the approach for the implementation of uncommitted investments to be suspended for this financial year. WHSSC will review the need and/or different options for delivering the scheme in 2024-2025. This scheme will now be considered within the process for prioritisation of all uncommitted expenditure and WHSSC had requested further information from Swansea Bay UHB (SBUHB), the provider HB to inform the evaluation, • Fertility Update - WHSSC Policy development: - CP37 Pre-implantation Genetic Testing-Monogenic Disorders, Commissioning Policy - CP38, Specialist Fertility Services: Assisted Reproductive Medicine, Commissioning Policy - The WHSSC team met with Llais on 31 August 2023 to discuss the next steps regarding the policy development. WHSSC informed Llais that due to the uncertainty surrounding the budget impact of any policy changes, the current financial challenges for the NHS in Wales meant that policy development had been halted. Colleagues in Llais understood the financial challenge and the difficult

Min Ref	Agenda Item
	<p>choices faced by WHSSC and HBs. A further update meeting was planned for late September 2023; and</p> <ul style="list-style-type: none"> • South Wales Spinal Network (SWSN) - Following discussions at the NHS Wales Health Collaborative Executive Group (CEG), Cardiff and Vale UHB (CVUHB) and SBUHB Regional and Specialised Services Provider Planning Partnership (RSSPPP) had set up a project to develop a new service model, to clarify the regional model for South East and South West Wales respectively, as well as the supra-regional model for South Wales, West Wales and South Powys. The project was launched in October 2020, with the aim of developing recommendations for delivering a safe, effective and sustainable model for spinal surgery in South and West Wales. The service specification for the ODN (CP241, Spinal Services Operational Delivery Network) was approved and published by WHSSC in June 2022. The South Wales Spinal Network (SWSN) Implementation Board proposed and agreed at the meeting held on 6 June 2023 that the SWSN will launch in September 2023. The network team were continuing to work with all HBs and pre-hospital providers to ensure that each component part of the network will be ready to go live on 25 September 2023. <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the report; and • Note that the South Wales Spinal Network (SWSN) will go live on 25 September 2023.
JC23/121	<p>3.3 Development of the Integrated Commissioning Plan (ICP) 2024/2025</p> <p>The report offering assurance regarding the development of the 2024/2025 Integrated Commissioning Plan (ICP) and the approach to its development within the wider NHS Wales situational context was received. Members noted that the process was on track in accordance with the timeline presented to the JC in May 2023 and an initial draft will be presented to the JC meeting on 21 November 2023.</p> <p>Members noted that the Annual Plan for WHSSC was being prepared in line with the changes to the Ministerial measures and would form part of the legacy statement supporting the establishment of the new Commissioning Joint Committee.</p> <p>Members noted that the detailed financial improvement options would be presented to the "In Committee" meeting session that day and the prioritisation process for this year would include in depth risk assessment processes using the learning from previous years</p>

Min Ref	Agenda Item
	<p>of financial austerity. The results of those risk assessments will be presented to the November JC meeting.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the report, • Receive assurance on the planning process to date which was in line with timeline received by the Joint Committee in May 2023; and • Note the approach being taken to respond to the NHS Wales situational context, including an enhanced risk assessment.
JC23/122	<p>3.4 South Wales Sexual Assault Referral Centres (SARC) Regional Model Implementation Briefing Paper</p> <p>The report providing an update on the implementation of the South Wales Sexual Assault Referral Centres (SARC) Regionalisation Programme following the Business Case approval in 2019, and which proposed that the WHSSC Joint Committee fulfil the CEO reporting function at the request of the NHS Wales Chief Executives; and which requested that the Joint Committee give final approval for Phase 1 implementation of the Programme was received.</p> <p>The Chair welcomed Stephen Harrhy (SH), Board Director / Chief Ambulance Service Commissioner, Corporate Development, NCCU & EASC and Joanna Williams (JW), Programme Director Welsh Sexual Health Assault Services (SARC) who were in attendance to present the report.</p> <p>Members noted that the briefing had previously been taken through the Collaborative Leadership Forum who received regular updates on the regionalisation programme and that the three Police Forces in South Wales and the Police and Crime Commissioners had agreed the preferred model and approved the 50% funding contribution for phase 1.</p> <p>Members noted that the SARC service being implemented was ISO accredited meaning that victims could be provided with evidence that could be taken through court. Evidence could be deemed as inadmissible by a court if it had not been taken from an ISO accredited facility, which could jeopardise any potential conviction.</p> <p>Stephen Harrhy (SH) confirmed the governance route and informed members that the uplift requested for HB approval was already included in their financial plans.</p> <p>CD queried whether the ISO accreditation was in line to be agreed by the October 2023 deadline. SH confirmed that the work was</p>

Min Ref	Agenda Item
	<p>ahead of schedule and provided an assurance that the ISO accreditation would be granted in October.</p> <p>NP queried which financial plan the funding sat in and James Leaves (JL) confirmed that the provision for the in year funding release had been collected from HBs through EASC and the slippage from that would begin to show in the future. SH agreed to provide a covering letter for the report submitted to HBs outlining the governance process and ratification for further clarity.</p> <p>Action – SH to draft a report to submit to Health Boards (HBs) to approve the updated South Wales Sexual Assault Referral Centres (SARC) Regionalisation Programme model.</p> <p>SR queried whether all reports relating to the SARC went through the Commissioning and Finance Group, SH confirmed that reporting did go through that route.</p> <p>SH advised members that an evaluation would be undertaken before moving forward and that regular reviews will be embedded.</p> <p>Karen Preece (KP) confirmed that the SARC was one of the services that the new Joint Committee will be commissioning and will oversee performance management, a service specification and evaluation will be brought through the usual process for approval, providing more clarity and structure around the governance and reviews.</p> <p>ChP queried the date listed within the report recommendations as 1 April 2023 and SH confirmed that prior to submission to HBs it would be changed to September 2023 to ensure that it was not being reported retrospectively.</p> <p>ACTION: SH to draft a separate briefing to HBs summarising and clarifying the financial arrangements for Phase 1.</p> <p>The Joint Committee resolved to;</p> <ul style="list-style-type: none"> • Note the report, • Approve the updated South Wales Sexual Assault Referral Centres (SARC) Regionalisation Programme model, prior to a report being issued to the seven HBs for final approval, • Consider and approve that the WHSSC Joint Committee will fulfil the CEO reporting function for the programme with immediate effect, prior to a report being issued to the seven HBs for final approval, • Recommend to HBs for approval of an in year funding uplift of £347k and a recurrent full year funding of up to

Min Ref	Agenda Item
	<p>£506k by 2025/26 for phase 1 of the implementation of the SARC Regionalisation Programme, prior to a report being issued to the seven HB's for final approval; and</p> <ul style="list-style-type: none"> • Recommend to HBs for approval of a continuation of funding for Phase 2 at the current level prior to a report being issued to the seven HBs for final approval.
JC23/123	<p>3.5 Welsh Government National Commissioning Review Update</p> <p>A verbal update outlining the progress of the Welsh Government (WG) National Commissioning review was received. Members noted that the programme structure was now in place to deliver all of the recommendations approved by the Minister.</p> <p>The first meeting of the National Commissioning Review Implementation Board meeting was due to take place immediately after the WHSSC Joint Committee meeting today.</p> <p>Carole Shillabeer (CS) queried the engagement of Chairs and the accountability process that was in place. KP confirmed that formal communication would come from Samia Edmonds (SE), Director of Planning and Performance, WG in her capacity as Chair of the Oversight Board. During the last Oversight Board, it was agreed that SE would attend a future meeting of the Chairs Group to be further informed.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the verbal update.
JC23/124	<p>3.6 Single Commissioner for Secure Mental Health Services Project Initiation Document (PID)</p> <p>The report presenting the Project Initiation Document (PID) for the Single Commissioner Model for Secure Mental Health Services was received alongside the Terms of Reference (ToR) for information.</p> <p>NP raised some concerns around the commissioning and operational management and where responsibility began and ended. DR provided assurance that clear lines of responsibility would be set as the project was developed at an operational level.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the report; and • Support the recommendation to initiate the project to develop a Single Commissioner Model for Secure Mental Health Services.

Min Ref	Agenda Item
JC23/125	<p>3.7 Revision to Financial Delegated Limits</p> <p>The report presenting the proposed changes to the financial limits for Individual Patient Funding Requests (IPFR) approvals was received.</p> <p>Hayley Thomas (HTh) queried the large number in 2022-23 below £50k and asked for further analysis for those requests. JL agreed to share further information following the meeting.</p> <p>ACTION: JL to share additional detail of IPFR approvals for 2022-23 under £50k with the Joint Committee.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the report, and • Approve the requested changes to the financial limits for Individual Patient Funding Request (IPFR) approvals.
JC23/126	<p>3.8 WHSSC Model Standing Orders – Governance and Accountability Framework</p> <p>The report providing an update on the WHSSC Model Standing Orders (SOs) and Governance and Accountability Framework was received. Members noted that WG had issued changes that WHSSC were required to adopt and once approved, they will be issued to HBs for approval and for inclusion as schedule 4.1 within their own respective SOs. The report will be presented to CTM Audit and Risk Assurance Committee for assurance in October 2023.</p> <p>The Joint Committee resolved to;</p> <ul style="list-style-type: none"> • Note the report, • Approve the proposed changes to the WHSSC Standing Orders (SOs), prior to being issued to the seven HBs for approval and inclusion as schedule 4.1 within their respective HB SOs, • Approve the proposed changes to the WHSSC Standing Financial Instructions (SFIs) prior to being issued to the seven HBs for approval and inclusion as schedule 4.1 Annex 2.1 within their respective HB SOs; and • Note that there were no changes to the Memorandum of Agreement (MoA).
JC23/127	<p>4.1 WHSSC Performance Report</p> <p>The report providing a summary of the performance of WHSSC's commissioned services was received and members noted the changes that had taken place since the last meeting, including:</p> <ul style="list-style-type: none"> • The Children and Adolescent Mental Health Service (CAHMS) at Ty Llidiard had been de-escalated thanks to the hard work put in by the Committee, Operational and Clinical Teams,

Min Ref	Agenda Item
	<ul style="list-style-type: none"> • Fertility services were currently in escalation, • Paediatric Intensive Care and Neonatal Services were being considered through the escalation framework and further information will be provided within the next Performance Report; and • The Plastic surgery Service in South Wales was in escalation and was the only service with current waiting times of over 104 weeks for inpatient treatment. <p>ChP queried whether the Welsh Fertility Institute (WFI) issues were the same issues raised previously. Sian Lewis (SL) confirmed that there were a number of unresolved historical issues and that further information would be brought to the WHSSC Quality & Patient Safety Committee (QPSC) meetings. SL assured members that WHSSC were working with the provider to try to address these issues.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the report.
JC23/128	<p>4.2 Financial Performance Report Month 4 2023-2024</p> <p>The Financial Performance Report setting out the financial position for WHSSC for month 4 2023-2024 was received and members noted the financial position reported against the 2023-2024 baselines following approval of the 2023-2026 WHSSC Integrated Commissioning Plan (ICP) by the Joint Committee in February 2023.</p> <p>The year to date financial position reported at Month 4 for WHSSC an overspend against the ICP financial plan of £1.069m and a forecast year-end overspend of £0.767m.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the contents of the report including the year to date financial position and forecast year-end position.
JC23/129	<p>4.3 South Wales Neonatal Transport Delivery Assurance Group Report (April – June 2023)</p> <p>The report providing a summary of the South Wales Neonatal Transport Delivery Assurance Group (DAG) quarterly report for 1 April 2023 – 30 June 2023 was received and members noted that the detailed information would be presented to the “In Committee” session of the Joint Committee.</p> <p>The Joint Committee resolved to;</p> <ul style="list-style-type: none"> • Note the highlights of the Q1 Neonatal Transport DAG report, • Note that the full report would be shared In-Committee due to potential patient identifiable data; and

Min Ref	Agenda Item
	<ul style="list-style-type: none"> • Receive assurance that the Neonatal Transport service delivery and outcomes were being scrutinised by the Delivery Assurance Group (DAG).
JC23/130	<p>4.4 South Wales Trauma Network Delivery Assurance Group Report (Q1)</p> <p>The report providing a summary of the Quarter 1 2023/24 Delivery Assurance Group (DAG) report of the South Wales Major Trauma Network (SWTN) was received.</p> <p>Members noted the following key updates;</p> <ul style="list-style-type: none"> • A Gateway 5 Review had been triggered by the SRO and timescales were under discussion with the WG review team, • The Trauma Audit Research Network (TARN) had been the subject of a cyber-attack and as a precautionary measure; the TARN network database had been taken offline. There was no evidence of the TARN data being compromised; and • Activity and utilisation of the Major Trauma Centre had been added to the DAG reports and further work was being undertaken by WHSSC on the risk share arrangements in the context of the ICP process. A report was being prepared for the October 2023 Management Group meeting that will encompass delivery assurance, commissioning and performance management arrangements for ODNs. <p>CD highlighted the concern around the loss of data, which could result in a huge impact on evaluation and clinical outcomes.</p> <p>NP and HTh asked that future reports include more detailed information around evaluation, outcomes and mortality information.</p> <p>ACTION: Additional detail around evaluation, mortality information and outcomes to be included in future reporting.</p> <p>The Joint Committee resolved to</p> <ul style="list-style-type: none"> • Note the full South Wales Major Trauma Network (SWTN) DAG Report and highlights contained in the cover report.
JC23/131	<p>4.5 Specialised Paediatric Services Strategy – Implementation Board Highlight Report</p> <p>The report providing a progress update on the implementation of the Specialised Paediatric Services Strategy was received and members noted the improvements that had been put in place.</p> <p>The Joint Committee resolved to;</p> <ul style="list-style-type: none"> • Note the report and the progress made.

Min Ref	Agenda Item
JC23/132	<p>4.6 All Wales PET Programme Progress Report</p> <p>The report providing an update on the progress made by the All Wales Positron Emission Tomography (PET) Programme was received and members noted that progress was being made according to the planned timeline with the main outstanding issue being the confirmation of capital funding from WG.</p> <p>The Joint Committee resolved to;</p> <ul style="list-style-type: none"> • Note the progress made by the All Wales Positron Emission Tomography (PET) Programme and its associate projects and workstreams.
JC23/133	<p>4.7 Corporate Governance Matters Report</p> <p>The report providing an update on Corporate Governance Matters since the previous meeting was received.</p> <p>Members noted that since the report was written a task and finish group had been set up reporting to the NHS Wales Board Secretaries Group to progress the development of the All Wales IPFR policy with the aim to submit and updated report to JC in November 2023.</p> <p>Jacqueline Maunder-Evans (JME) informed members that a representative from Audit Wales would be joining the Joint Committee Meeting in November to provide an update on progress against the recommendations in the Audit Wales “WHSSC Committee Governance Arrangements” Report.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the report.
JC23/134	<p>4.8 Reports from the Joint Sub-Committees</p> <p>The Joint Committee Sub-Committee reports were received as follows:</p> <p>4.8.1 Audit and Risk Committee (ARC) Assurance Report</p> <p>The JC noted the assurance report from the CTMUHB Audit and Risk Committee meeting held on 16 August 2023.</p> <p>4.8.2 Management Group Briefings</p> <p>The JC noted the core briefing documents from the meetings held on 27 July 2023 and 24 August 2023.</p> <p>4.8.3 Individual Patient Funding Request (IPFR) Panel</p> <p>The JC noted the Chair’s report from the meeting held on 17 August 2023. Members noted that the advert for the IPFR Chair vacancy had gone out.</p>

Min Ref	Agenda Item
	<p>4.8.4 Integrated Governance Committee (IGC) The JC noted the Chair’s report from the meeting held on 15 August 2023.</p> <p>4.8.5 Quality & Patient Safety Committee (QPSC) The JC noted the Chair’s report from the meeting held on 16 August 2023 and the summary of services in escalation that was attached as an appendix. Members noted the concerns raised in the Plastics outreach services and the escalation was being taken through WG.</p> <p>KP informed members that the Network Manager position for the Welsh Kidney Network had not been advertised as planned.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the reports.
JC23/135	<p>5.1 Any Other Business</p> <ul style="list-style-type: none"> • Cheshire & Wirral Mother and Baby Unit (MBU) – Members noted that a contractor had been identified and commencement on site was expected before Christmas. Recruitment to the posts was expected to start in April 2024 with view to new unit being operational by 1 October 2024; and • WHSSC Annual Report – members noted that the WHSSC Annual Report would be circulated via email for approval and brought back to the November meeting for ratification.
JC23/136	<p>5.2 Date of Next Meeting (Scheduled) The Joint Committee noted that the next scheduled meeting would be held on 21 November 2023.</p> <p>There being no other business other than the above the meeting was closed at 11.02hrs.</p>
JC23/137	<p>5.3 In Committee Resolution The Joint Committee is recommended to make the following resolution: “That representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1 (2) Public Bodies (Admission to Meetings) Act 1960)”.</p>

Chair’s Signature:

Date:.....